# US 2005/0032039 A1 · HIV-specific T-cell induction

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0032039 A1
- Document ID: US20050032039A1
- Status: Published application
- Kind: A1
- Application number: 10/673,671
- Filed: 2003-09-29
- Published: 2005-02-10
- Earliest claimed: 1998-11-16
- Assignees: Board of Regents, The University of Texas System
- Inventors: K. Sastry; Ralph Arlinghaus; Pramod Nehete
- Web page: https://patentgrep.com/patent/US20050032039A1

## CPC

- C07K 14/005: from viruses
- A61K 40/00: Cellular immunotherapy (medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 40/19: Dendritic cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/46: Viral antigens
- A61P 31/18: for HIV
- G01N 33/5091: {for testing the pathological state of an organism}
- G01N 33/56977: {HLA or MHC typing}
- G01N 33/56988: {HIV or HTLV}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2239/31: characterized by the route of administration
- C12N 2740/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- G01N 2333/16: HIV-1, HIV-2
- G01N 2333/162: env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site
- Y10S 530/826: Viruses
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

This invention discloses diagnostic, preventative, and treatment therapies of AIDS involving determining whether a subject exhibits an HLA-Cw7-restricted CTL response. Some methods are directed to the use of HLA-Cw7 as a genetic marker for long-term non-progression and amenability to treatment therapies. Diagnostic methods include a method for predicting long term non-progression in an HIV-infected subject. Preventative and treatment methods encompass determining whether a subject exhibits or can exhibit an HLA-Cw7-restricted CTL response. They also encompass ways of eliciting such a response, if necessary. Furthermore, some of the methods involve administering one or more HIV polypeptides or peptides, or polynucleotides encoding them, as a treatment therapy to prevent the development of AIDS.

## Claims

### Claim at position 1

1-74. (Cancelled)

### Claim 75

A method of treating an HIV-infected human subject to reduce the likelihood that said subject will develop AIDS, the method comprising the steps of administering to said subject a pharmaceutically acceptable composition which delivers one or more peptides having peptide sequences selected from the group consisting of one or more of the following groups of peptide sequences:
a) SEQ ID NO:26, 27, 28, 29, 30, 31, 32, 33 or 34;
b) SEQ ID NO:20, 21, 22, 23, 24, 25 or 40;
c) SEQ ID NO:1, 2 or 3;
d) SEQ ID NO:4, 5, 6, or 7;
e) SEQ ID NO:8, 9, 10, 11, 12, 13, 14, 15 or 38; and
f) SEQ ID NO:16, 17, 18, 19 or 20;
wherein the delivery of said peptide(s) promotes the induction of an HIV-directed cytotoxic T-lymphocyte response.

### Claim 76 (depends on 75)

The method of claim 75, further comprising determining whether said subject exhibits an HLA-Cw7-restricted CTL response.

### Claim 77 (depends on 75)

The method of claim 75, wherein the peptides delivered to said subject comprise up to 50 residues.

### Claim 78 (depends on 77)

The method of claim 77, wherein the peptides are 11 to 25 residues in length.

### Claim 79 (depends on 75)

The method of claim 75, wherein the delivered peptides are 11 to 25 residues in length and comprise at least three peptide sequences, wherein at least one peptide sequence is selected from each of the following three groups:
(a) SEQ ID NO:26, 27, 28, 29, 30, 31, 32, 33 or 34;
(b) SEQ ID NO:20, 21, 22, 23, 24, 25 or 40; and
(c) SEQ ID NO:1, 2 or 3.

### Claim 80 (depends on 75)

The method of claim 75, wherein a plurality of peptide sequences are delivered to said subject comprising at least two peptide sequences, one selected from each of the following two groups of peptide sequences:
(a) SEQ ID NO:26, 27, 28, 29, 30, 31, 32, 33 or 34; or
(b) SEQ ID NO:1, 2 or 3.

### Claim 81 (depends on 75)

The method of claim 75, wherein a plurality of peptide sequences are delivered to said subject comprising at least two peptide sequences, one selected from each of the following two groups of peptide sequences:
(a) SEQ ID NO:8, 9, 10, 11, 12, 13, 14, 15 or 38; or
(b) SEQ ID NO:16, 17, 18, 19 or 39.

### Claim 82 (depends on 80)

The method of claim 80, wherein the plurality of peptide sequences delivered to said subject comprises at least three peptide sequences, one selected from each of the following three groups of peptide sequences:
(a) SEQ ID NO:26, 27, 28, 29, 30, 31, 32, 33 or 34;
(b) SEQ ID NO:20, 21, 22, 23, 24, 25 or 40; and
(c) SEQ ID NO:1, 2 or 3.

### Claim 83 (depends on 82)

The method of claim 82, wherein the plurality of peptide sequences delivered to said subject comprises at least four peptide sequences, one selected from each of the following four groups of peptide sequences:
(a) SEQ ID NO:26, 27, 28, 29, 30, 31, 32, 33 or 34;
(b) SEQ ID NO:20, 21, 22, 23, 24, 25 or 40;
(c) SEQ ID NO:1, 2 or 3; and
(d) SEQ ID NO:4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 38, 16, 17, 18, 19 or 39.

### Claim 84 (depends on 44)

The method of claim 44, wherein the plurality of peptide sequences delivered to said subject comprises at least five peptide sequences, one selected from each of the following five groups of peptide sequences:
(a) SEQ ID NO:26, 27, 28, 29, 30, 31, 32, 33 or 34;
(b) SEQ ID NO:20, 21, 22, 23, 24, 25 or 40;
(c) SEQ ID NO:1, 2 or 3;
(d) SEQ ID NO:4, 5, 6 or 7; and
(e) SEQ ID NO:8, 9, 10, 11, 12, 13, 14, 15, 38, 16, 17, 18, 19 or 39.

### Claim 85 (depends on 84)

The method of claim 84, wherein the plurality of peptide sequences delivered to said subject comprises at least six peptide sequences, one selected from each of the following four groups of peptide sequences:
(a) SEQ ID NO:26, 27, 28, 29, 30, 31, 32, 33 or 34;
(b) SEQ ID NO:20, 21, 22, 23, 24, 25 or 40;
(c) SEQ ID NO:1, 2 or 3;
(d) SEQ ID NO:4, 5, 6, or 7;
(e) SEQ ID NO:8, 9, 10, 11, 12, 13, 14, 15 or 38; and
(f) SEQ ID NO:16, 17, 18, 19 or 20.

### Claim 86 (depends on 75)

The method of claim 75, wherein said peptide(s) are delivered to said subject by means of a viral vector which encodes the peptide(s).

### Claim 87 (depends on 86)

The method of claim 86, wherein the viral vector is selected from the group consisting of vaccinia virus, adenovirus, herpesvirus, retrovirus, adeno-associated virus and lentivirus.

### Claim 88 (depends on 87)

The method of claim 87, wherein the viral vector is adenovirus.

### Claim 89 (depends on 75)

The method of claim 75, wherein said peptide(s) are delivered to said subject by means of a pharmaceutically acceptable composition which comprises the peptide(s).

### Claim 90 (depends on 89)

The method of claim 89, wherein said peptide(s) are coupled to a carrier molecule.

### Claim 91 (depends on 90)

The method of claim 90, wherein said carrier molecule is KLH or BSA.

### Claim 92 (depends on 89)

The method of claim 89, wherein said composition further comprises an adjuvant.

### Claim 93 (depends on 92)

The method of claim 92, wherein said adjuvant is selected from a group consisting of lipids, toxins, cytokines, oligonucleotides and bacterial DNA.

### Claim 94 (depends on 75)

The method of claim 75, further comprising administering AZT to said subject.

### Claim 95 (depends on 75)

The method of claim 75, further comprising carrying out HAART on said subject.

### Claim 96 (depends on 75)

The method of claim 75, wherein the subject does not exhibit an HLA-Cw7-restricted CTL response, further comprising:
(a) determining if the subject expresses the HLA-Cw7 haplotype; and if so,
(b) eliciting said response.

### Claim 97 (depends on 96)

The method of claim 96, wherein eliciting said response comprises administering to said subject a therapeutically effective amount of α- or γ-interferon, whereby the level of HLA-Cw7 haplotype expression increases.

### Claim 98 (depends on 75)

The method of claim 75, wherein the composition is injected into the subject intradermally or subcutaneously.

### Claim 99 (depends on 75)

The method of claim 75, wherein the composition is administered more than one time.
